Literature DB >> 17196061

Alzheimer's disease a century later.

Richard J Caselli1, Thomas G Beach, Roy Yaari, Eric M Reiman.   

Abstract

OBJECTIVE: To provide a current survey of the clinical and pathologic features, known genetic and suggested pathogenic contributions, diagnosis, and treatment of Alzheimer's disease (AD) and related forms of dementia. DATA SOURCES: PubMed was searched for specific indexing terms identified by the authors as relevant to the topic. Also included were diagnostic and consensus criteria and classic references long standing in the Alzheimer's disease literature. DATA SYNTHESIS: AD is the most common form of disabling cognitive impairment in older persons, and its prevalence is rapidly growing as people live to older ages. Clinically, the disorder is characterized by a gradual but progressive decline in memory and other cognitive domains and the frequent occurrence of noncognitive behavioral symptoms. Neuropathologically, the cardinal features of AD include neuritic plaques, neuro-fibrillary tangles, and the loss of synapses and neurons. The clinical evaluation of AD includes a history and physical examination, laboratory tests, and structural brain imaging to exclude less common forms of dementia. The clinical management of AD includes medication and nonmedication strategies for addressing cognitive, behavioral, and other commonly associated symptoms of patients as well as lifestyle changes such as driving cessation and residential care. Genetic causes of familial Alzheimer's disease as well as genes that predispose to late-onset and sporadic Alzheimer's disease have led to greater understanding of the pathophysiology of the neurodegenerative process.
CONCLUSIONS: While there has been great promise in the scientific understanding, early detection, and tracking of AD and in the discovery of promising disease-slowing treatments, there remains an unmet urgent need to identify effective primary and secondary prevention therapies in order to avert a financially overwhelming public health problem.

Entities:  

Mesh:

Year:  2006        PMID: 17196061     DOI: 10.4088/jcp.v67n1118

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  34 in total

1.  Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow.

Authors:  C Dirk Keene; Rubens C Chang; Americo H Lopez-Yglesias; Bryan R Shalloway; Izabella Sokal; Xianwu Li; Patrick J Reed; Lisa M Keene; Kathleen S Montine; Richard M Breyer; Jason K Rockhill; Thomas J Montine
Journal:  Am J Pathol       Date:  2010-06-03       Impact factor: 4.307

2.  Therapeutic application of neural stem cells and adult neurogenesis for neurodegenerative disorders: regeneration and beyond.

Authors:  Sarah E Latchney; Amelia J Eisch
Journal:  Eur J Neurodegener Dis       Date:  2012

3.  Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.

Authors:  Erik Portelius; Henrik Zetterberg; Robert A Dean; Alexandre Marcil; Philippe Bourgeois; Magdalena Nutu; Ulf Andreasson; Eric Siemers; Kwasi G Mawuenyega; Wendy C Sigurdson; Patrick C May; Steven M Paul; David M Holtzman; Kaj Blennow; Randall J Bateman
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 4.  Role of HMG-CoA reductase inhibitors in neurological disorders : progress to date.

Authors:  Allison B Reiss; Elzbieta Wirkowski
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Dementia: continuum or distinct entity?

Authors:  Glenn D Walters
Journal:  Psychol Aging       Date:  2010-09

6.  The plasma membrane redox system is impaired by amyloid β-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice.

Authors:  Dong-Hoon Hyun; Mohamed R Mughal; Hyunwon Yang; Ji Hyun Lee; Eun Joo Ko; Nicole D Hunt; Rafael de Cabo; Mark P Mattson
Journal:  Exp Neurol       Date:  2010-07-27       Impact factor: 5.330

Review 7.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Interleukin 18 in the CNS.

Authors:  Silvia Alboni; Davide Cervia; Shuei Sugama; Bruno Conti
Journal:  J Neuroinflammation       Date:  2010-01-29       Impact factor: 8.322

9.  Confounding.

Authors:  Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2007-04       Impact factor: 1.759

Review 10.  Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies.

Authors:  Tracy Fischer-Smith; Christie Bell; Sidney Croul; Mark Lewis; Jay Rappaport
Journal:  J Neurovirol       Date:  2008-08       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.